MedTrace Logo

Fecal Microbial Transplant in Pediatric Crohn's Disease

NCT02272868 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2021-09-29

No results posted yet for this study

Summary

This is a double blind placebo control trial of fecal microbial transplantation for active Crohn's disease in patients 12 to 21 years of age.

Conditions

Interventions

BIOLOGICAL

Fecal Microbial transplant

Pretransplant regimen(rifaxamin+omeprazole+miralax) + Donor feces transplant

DRUG

Normal Saline

Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline

DRUG

rifaximin+omeprazole+miralax

Sponsors & Collaborators

  • Seattle Children's Hospital

    lead OTHER

Principal Investigators

  • David Suskind, MD · Seattle Children's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-10-01
Completion
2016-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02272868 on ClinicalTrials.gov